UroGen Pharma Ltd. has received a significant update regarding its shareholder structure. The Toronto-Dominion Bank and its subsidiary, TD Securities Inc., have jointly filed an updated Schedule 13G/A with the SEC, revealing that they now hold a combined 5.9% stake in the company. This filing, dated November 13, 2026, indicates that the Toronto-Dominion Bank has the sole voting power over 2,770,530 shares, while TD Securities Inc. controls 115,706 shares.

This development is noteworthy as it underscores the ongoing investment interest in UroGen Pharma, a company engaged in the pharmaceutical preparations industry. The increased stake by a major financial institution like Toronto-Dominion Bank could enhance the company's credibility and attract further investment, potentially impacting its market position.

Background

UroGen Pharma Ltd. operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company is listed on the Nasdaq under the ticker symbol URGN. Recent filings indicate that UroGen Pharma is classified as a smaller reporting company and a non-accelerated filer. The latest filing, a Schedule 13G/A, was submitted on November 13, 2026, following a series of other filings, including a 10-Q and an 8-K earlier in November.

What the Filing Says

The filing reveals that The Toronto-Dominion Bank holds 2,770,530 shares, representing 5.7% of UroGen Pharma's ordinary shares, while TD Securities Inc. holds 115,706 shares, accounting for 0.2%. The total beneficial ownership reported amounts to 2,886,236 shares, which gives the banks significant voting and disposal power over these shares. The document states, "This schedule is jointly filed by TD Bank and TDSI," indicating a collaborative approach to their investment strategy.

Impact

This increase in stake may affect various stakeholders, including UroGen Pharma's management, existing shareholders, and potential investors. The involvement of a prominent institution like The Toronto-Dominion Bank may enhance investor confidence in UroGen's strategic direction and operational capabilities. Additionally, the filing suggests that the banks do not intend to influence the control of UroGen Pharma, as they have stated, "neither the filing of this statement nor anything herein shall be construed as an admission... with respect to the Issuer or any securities of the Issuer." This clarification may help maintain stability in shareholder relations.

What's Next

The filing does not specify what actions might follow this update. However, the increased stake by The Toronto-Dominion Bank and TD Securities Inc. could lead to further developments in UroGen Pharma's strategic initiatives or partnerships in the future.